Earnings Call · Q4 FY2023·2024-02-02

Q4 23EPS +10.33%·Rev n/aQ3 23EPS +7.51%·Rev n/aQ2 23EPS +3.43%·Rev n/aQ1 23EPS +5.54%·Rev n/a⚠ consensus missing

REGENERON PHARMACEUTICALS, INC. REGN

Ryan Crowe — Vice President, Investor Relations

Leonard Schleifer — Co-Founder, President and Chief Executive Officer

George Yancopoulos — President and Chief Scientific Officer

Marion McCourt — Executive Vice President, Commercial

Bob Landry — Executive Vice President, Chief Financial Officer

−1.1%1d on move date−2.6% vs SPY3d−0.8%5d+2.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more REGN calls or request research access.

More REGN calls Browse calls Request research access